Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep 1;446(2):165-77.
doi: 10.1042/BJ20120653.

Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

Andrew F Teich  1 , Ottavio Arancio
Affiliations
Review

Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

Andrew F Teich et al. Biochem J. .

Abstract

The conventional view of AD (Alzheimer's disease) is that much of the pathology is driven by an increased load of β-amyloid in the brain of AD patients (the 'Amyloid Hypothesis'). Yet, many therapeutic strategies based on lowering β-amyloid have so far failed in clinical trials. This failure of β-amyloid-lowering agents has caused many to question the Amyloid Hypothesis itself. However, AD is likely to be a complex disease driven by multiple factors. In addition, it is increasingly clear that β-amyloid processing involves many enzymes and signalling pathways that play a role in a diverse array of cellular processes. Thus the clinical failure of β-amyloid-lowering agents does not mean that the hypothesis itself is incorrect; it may simply mean that manipulating β-amyloid directly is an unrealistic strategy for therapeutic intervention, given the complex role of β-amyloid in neuronal physiology. Another possible problem may be that toxic β-amyloid levels have already caused irreversible damage to downstream cellular pathways by the time dementia sets in. We argue in the present review that a more direct (and possibly simpler) approach to AD therapeutics is to rescue synaptic dysfunction directly, by focusing on the mechanisms by which elevated levels of β-amyloid disrupt synaptic physiology.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Amyloid β-protein generation by normal proteolytic processing of β-APP
APP is shown at the top, with the β-amyloid region in red. APP can be processed through two mutually exclusive pathways. The α-secretase pathway involves an initial cleavage by α-secretase which goes through the β-amyloid region, precluding further processing that can yield β-amyloid. This initial cleavage event releases sAPP-α into the cytosol, and leaves behind the membrane-bound C83 protein. Processing of C83 by γ -secretase yields the p3 fragment and the AICD. β-Secretase cleavage of APP yields sAPP-β and C99, and subsequent processing of C99 yields β-amyloid and the AICD fragment.
Figure 2
Figure 2. β-Amyloid can inhibit synaptic plasticity through a variety of mechanisms
CREB phosphorylation may be inhibited through inhibition of the PKA pathway, the Uch-L1 proteasomal system, aberrant calpain activity, or inhibition of the cGK pathway. In addition, high β-amyloid levels may reduce histone acetylation, which can impair gene expression necessary for learning and memory. See the text for details.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer's disease. Lancet. 1997;349:1546–1549. - PubMed
    1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych. Gerichtl. Med. 1907;64:146–148.
    1. Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters. Z. Gesamte Neurol. Psychiatr. 1911;4:356–385.
    1. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984;120:885–890. - PubMed
    1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1985;82:4245–4249. - PMC - PubMed

Publication types

MeSH terms